Complaint
| Generic Name | Valsartan and Amlodipine Tablets 85mg |
| Strength | 85mg |
| Packing | 7tablets/blister,2blisters/box |
| Origin | China |
Treating essential hypertension. This product is indicated for patients whose blood pressure cannot be adequately controlled by monotherapy.
Amlodipine 2.5-10 mg once daily is effective for treating hypertension, while valsartan is effective at 80-320 mg. In clinical trials of once-daily valsartan amlodipine tablets, the antihypertensive effect increased with the dose of amlodipine 5-10 mg and valsartan 80-320 mg.
Adverse reactions to valsartan are usually dose-independent; Adverse effects of amlodipine are both dose-dependent (mainly peripheral edema) and dose-independent, with the former being more common than the latter.
Patients who cannot adequately control their blood pressure with monotherapy can use this product instead.
Addition therapy: Patients who do not have adequate blood pressure control during amlodipine monotherapy or valsartan monotherapy can be switched to combination therapy with this product.
Patients who experience dose-limiting adverse reactions to amlodipine or valsartan monotherapy may be switched to this drug to achieve blood pressure control with a lower dose of one component combined with another.
Alternative therapy: To facilitate administration, patients receiving amlodipine and valsartan monotherapy can be switched to the same dose of this product.
For information about discontinuing beta receptor antagonists, see Precautions.
Both amlodipine and valsartan can be taken with food or on an empty stomach. It is recommended that this product be taken with water.
Liver and kidney function injury:
Patients with mild to moderate renal impairment do not need to adjust the dose. It should be used with caution in cases of severe renal impairment (see contraindication). Patients with liver injury or biliary obstructive disease should also use this product with caution (see precautions).
Allergy to the active ingredient or any excipient is prohibited.
It is prohibited for pregnant and lactating women (see instructions for women on medication).
No severe renal impairment (creatinine clearance < 10 ml/min) patient medication data. This product should be contraindicated in patients with hereditary angioedema and those who develop angioedema early on treatment with ACE inhibitors or angiotensin II receptor antagonists.
Medication for special population:
Gestation period:
Because of the mechanism of action of angiotensin II antagonists, harm to the fetus cannot be ruled out. Angiotensin converting enzyme inhibitors (a specific class of drugs that act on RAAS) given in utero during the second and third trimesters have been reported to cause injury or death to the developing fetus. In addition, there was a potential risk of birth defects associated with the use of angiotensin converting enzyme inhibitors during the first trimester of pregnancy in the retrospective data. Spontaneous abortion, oligohydramnios, and neonatal renal insufficiency have been reported in pregnant women inadvertently taking valsartan. Similar to other drugs that act directly on RAAS, this product should not be used by pregnant women (see contraindications). For women of childbearing age, doctors should inform them of the potential risks of RAAS during pregnancy when prescribing drugs that act on them. If pregnancy is found during the administration, the product should be stopped immediately.
Lactation period:
It is not clear whether valsartan and/or amlodipine are excreted through human milk. Valsartan is excreted by the milk of lactating rats, so it is contraindicated in lactating women.
